Mithramycin analogues with reduced toxicity for the treatment of ETS transcription factor driven tumors
Abstract
Chromosomal translocations involving the ETS family of transcription factors are common in Ewing sarcoma, prostate cancer, and leukemia. These translocations lead in overexpression of aberrant ETS transcription factors, which drive tumorigenesis. Mithramycin (MTM) was shown to inhibit EWS/FLI1, the most common ETS related transcription factor in Ewing sarcoma, presumably through interference at its DNA binding sites on promoter regions. However, MTM has a short half‐life and a narrow therapeutic window marked by severe liver and hematological toxicities. Considering that MTM has a pKa of 5, we hypothesized that its rapid pharmacokinetic (PK) clearance is attributed to liver uptake by organic anion transporter polypeptides (OATP), which may also contribute to the observed hepatotoxicity. Here, we sought to develop analogues with specificity toward ETS transcription factors and reduced toxicity by attempting to modify the physicochemical properties of MTM.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 01, 2018
- Source ID
- 10.1096/fasebj.2018.32.1_supplement.836.18
Entities
People
- Jon S. Thorson
- Joseph M. Eckenrode
- Jürgen Rohr
- Markos Leggas
- Prithiba Mitra
- Reiya Hayden
Organizations
- United States Department of Defense
- University of Kentucky